Dentsply Sirona Inc Stock Price, News & Analysis

Dentsply Sirona has partnered with Smile Train and FDI World Dental Federation to launch the first global protocols for digital cleft treatment. This initiative aims to enhance the quality and accessibility of cleft care worldwide. The protocols, developed through extensive research and expert consensus, will guide dental professionals at every treatment stage, covering areas such as presurgical orthopedics and oral rehabilitation. An interactive tool has been created to facilitate the application of this information, ensuring a user-friendly experience for practitioners. Dentsply Sirona has been instrumental in funding cleft surgeries and is committed to improving care for underserved communities globally, aligning with its sustainability strategy.

Dentsply Sirona, the largest manufacturer of professional dental products, announced an investor conference call on May 3, 2023, at 8:30 am ET. This call will discuss the company’s first quarter financial results. The live webcast can be accessed via the Investors section of their website. Registrants can secure their participation through this link, and a replay will be made available afterward.

Dentsply Sirona has a long-standing history of innovation in the dental industry and continues to provide high-quality solutions for patient care. Their products are marketed under various world-class brands, enhancing dental and oral health worldwide.

Dentsply Sirona (Nasdaq: XRAY) announced a $150 million accelerated share repurchase (ASR) agreement with Goldman Sachs, aimed at enhancing shareholder value. Under this agreement, the company will initially acquire around 3.1 million shares. The final share count will be determined based on the stock's average price during the ASR's valuation period, with potential adjustments affecting total expenditure. The completion of this ASR is expected by the end of Q2 2023, reflecting Dentsply Sirona's commitment to returning capital to shareholders and optimizing its capital structure.

DENTSPLY SIRONA reported a challenging FY22 with net sales decreasing by 7.3% to $3,922 million, compared to $4,231 million in FY21. The company experienced a net loss of $950 million or ($4.41) per share, significantly down from a net income of $411 million in FY21. Q4 showed a 10.9% drop in net sales to $983 million, with adjusted EPS falling 44.4% to $0.46. For FY23, the outlook suggests net sales between $3.85 billion and $3.95 billion, with adjusted EPS anticipated in the range of $1.80 to $2.00.

Dentsply Sirona (Nasdaq: XRAY) announced a major organizational restructuring plan aimed at boosting operational efficiency and shareholder value. The plan is expected to yield between $200 million and $225 million in annual cost savings over the next 18 months. Key components include an 8%-10% workforce reduction, establishment of five global business units, and an optimized management structure. Additionally, the company anticipates $165 million in non-recurring charges, mainly in 2023, while aiming for adjusted earnings of $3.00 per share by 2026. The restructuring aligns with Dentsply Sirona's strategy to address a challenging external environment while fostering sustainable growth.

Dentsply Sirona, a leading manufacturer of dental products, will host an investor conference call and live webcast on February 28, 2023, at 8:30 am ET. This event aims to discuss the company’s fourth quarter and full year 2022 financial results. Interested participants can find the presentation and register for the call on Dentsply Sirona's Investor Relations website at https://investor.dentsplysirona.com. A replay of the webcast will also be accessible afterward. Dentsply Sirona is headquartered in Charlotte, North Carolina, and is known for its innovative dental technologies.

Dentsply Sirona (Nasdaq: XRAY) presented at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023. The company forecasts net sales exceeding $3.88 billion, surpassing its previous outlook range of $3.85 billion to $3.88 billion. The adjusted EPS for the full year 2022 is anticipated to remain within the prior guidance of $1.90 to $2.00. Presentation materials and webcast details are accessible on the company's investor website.